

## **1. NAME OF THE MEDICINAL PRODUCT**

Mitotane Esteve 500 mg tablets

## **2 QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each tablet contains 500 mg of mitotane.  
For the full list of excipients, see section 6.1.

## **3 PHARMACEUTICAL FORM**

Tablet.

White, biconvex, round, scored tablets.  
They are bisected on one side and impressed "BL" over "L1" on the other side.

## **2. CLINICAL PARTICULARS**

### **2.1 Therapeutic indications**

Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenocortical carcinoma (ACC).

The effect of Mitotane Esteve on non functional adrenal cortical carcinoma is not established.

## **3. CLINICAL PARTICULARS**

### **4.2 Posology and method of administration**

Treatment should be initiated and followed by a suitably experienced specialist.

#### Posology

Treatment in adults should be started with 2 - 3 g mitotane per day and increased progressively (e.g. at two-week intervals) until mitotane plasma levels reach the therapeutic window 14 – 20 mg/L.

If it is urgent to control Cushing's symptoms in highly symptomatic patients, higher starting doses between 4 - 6 g per day could be necessary and daily dose increased more rapidly (e.g. every week). A starting dose higher than 6 g/day is generally not recommended.

*Dose adjustments, monitoring and discontinuation*

Dose adjustment is aimed to reach a therapeutic window (mitotane plasma levels 14 - 20 mg/L) which ensures optimal use of Mitotane Esteve with acceptable safety. There are some data suggesting that a mitotane plasma level above 14 mg/L may result in enhanced efficacy (see section 5.1). Mitotane plasma levels higher than 20 mg/L may be associated with severe undesirable effects, including neurological toxicity, and offer no further benefit in terms of efficacy, therefore this threshold should not be exceeded. Mitotane plasma levels should therefore be monitored in order to adjust the Mitotane Esteve dose and to avoid reaching toxic levels. For further information on the sample testing please contact the Marketing Authorisation Holder or its local representative (see section 7).

Dosing should be individually adjusted based on mitotane plasma levels monitoring and clinical tolerance until mitotane plasma levels reach the therapeutic window 14 - 20 mg/L. The target plasma concentration is usually reached within a period of 3 to 5 months.

Mitotane plasma levels should be assessed after each dose adjustment and at frequent intervals (e.g. every two weeks), until the optimal maintenance dose is reached. Monitoring should be more frequent (e.g. every week) when a high starting dose has been used. It should be taken into account that dose adjustments do not produce immediate changes in plasma levels of mitotane (see section 0). In addition, because of tissue accumulation, mitotane plasma levels should be monitored regularly (e.g. monthly) once the maintenance dose has been reached.

Regular monitoring (e.g. every two months) of mitotane plasma levels is also necessary after interruption of treatment. Treatment can be resumed when mitotane plasma levels range between 14 - 20 mg/L. Due to the prolonged half-life, significant serum concentrations may persist for weeks after cessation of therapy.

If serious adverse reactions occur, such as neurotoxicity, treatment with mitotane may need to be temporarily interrupted. In case of mild toxicity, the dose should be reduced until the maximum tolerated dose is attained.

Treatment with Mitotane Esteve should be continued as long as clinical benefits are observed. If no clinical benefits are observed after 3 months at optimal dose, treatment should be permanently discontinued.

### Special populations

#### *Paediatric population*

The experience in children is limited.

The paediatric posology of mitotane has not been well characterised but appears equivalent to that of adults after correction for body surface area.

Treatment should be initiated at 1.5 to 3.5 g/m<sup>2</sup>/day in children and adolescents with the objective of reaching 4 g/m<sup>2</sup>/day. Mitotane plasma levels should be monitored as for adults, with particular attention when plasma levels reach 10 mg/L as a quick increase in plasma levels may be observed. Dose may be reduced after 2 or 3 months according to the mitotane plasma levels or in case of serious toxicity.

#### *Hepatic impairment*

There is no experience in the use of mitotane in patients with hepatic impairment, so data are insufficient to give a dose recommendation in this group. Since mitotane is mainly metabolised through the liver, mitotane plasma levels are expected to increase if liver function is impaired. The use of mitotane in patients with severe hepatic impairment is not recommended. In patients with mild to moderate hepatic impairment, caution should be exercised and monitoring of liver function should be performed. Monitoring of mitotane plasma levels is specially recommended in these patients (see section 0).

### *Renal impairment*

There is no experience in the use of mitotane in patients with renal impairment, so data are insufficient to give a dose recommendation in this group. The use of mitotane in patients with severe renal impairment is not recommended and, in cases of mild to moderate renal impairment, caution should be exercised. Monitoring of mitotane plasma levels is specially recommended in these patients (see section 0).

### *Elderly patients (≥ 65 years old)*

There is no experience on the use of mitotane in elderly patients, so data are insufficient to give a dose recommendation in this group. Caution should be exercised and frequent monitoring of mitotane plasma levels is especially recommended in these patients.

### Method of administration

The total daily dose may be divided in two or three doses according to patient's convenience. Tablets should be taken with a glass of water during meals containing fat-rich food (see section **Error! Reference source not found.**). Patients should be advised not to use any tablets showing signs of deterioration, and caregivers to wear disposable gloves when handling the tablets.

## **4.3 Contraindications**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Lactation (see section 4.6)

Concomitant use with spironolactone (see section 4.5)

## **4. CLINICAL PARTICULARS**

### **4.4 Special warnings and precautions for use**

*Before the initiation of the treatment:* Large metastatic masses should be surgically removed as far as possible before starting mitotane treatment, in order to minimise the risk of infarction and haemorrhage in the tumour due to a rapid cytotoxic effect of mitotane.

*Risk of adrenal insufficiency:* All patients with non functional tumour and 75% of patients with functional tumour show signs of adrenal insufficiency. Therefore, steroid replacement may be necessary in these patients. Since mitotane increases plasma levels of steroid binding proteins, free cortisol and corticotropin (ACTH) determinations are necessary for optimal dosing of steroid substitution (see section **Error! Reference source not found.**). Glucocorticoid insufficiency is more frequent, but mineralocorticoid insufficiency may also be associated and the steroid substitution may need to be adapted accordingly.

*Shock, severe trauma or infection:* Mitotane should be temporarily discontinued immediately following shock, severe trauma or infection, since adrenal suppression is its prime action. Exogenous steroids should be administered in such circumstances, since the depressed adrenal gland may not immediately start to secrete steroids. Because of an increased risk of acute adrenocortical insufficiency, patients should be instructed to contact their physician immediately if injury, infection, or any other concomitant illness occurs.

*Monitoring of plasma levels:* Mitotane plasma levels should be monitored in order to adjust the mitotane dose, particularly if high starting doses are considered necessary. Dose adjustments may be necessary to achieve the desired therapeutic levels in the window between 14 - 20 mg/L and avoid specific adverse reactions (see section 4.2). For further information on the sample testing please contact the Marketing Authorisation Holder or its local representative (see section 7).

*Hepatic or renal impairment:* There are insufficient data to support the use of mitotane in patients with severe hepatic or renal impairment. In patients with mild or moderate hepatic or renal impairment, caution should be exercised and monitoring of mitotane plasma levels is particularly recommended (see section 4.2).

*Hepatotoxicity* has been observed in patients treated with mitotane. Cases of liver damage (hepatocellular, cholestatic and mixed) and autoimmune hepatitis were observed. Liver function tests (alanine transaminase [ALT], aspartate transaminase [AST], bilirubin, and alkaline phosphatase [ALP] levels) should be periodically monitored, especially during the first months of treatment or when it is necessary to increase the dose. If AST and/or ALT are increased > 5 ULN, or ALP or bilirubin > 2 ULN, there is risk of liver injury/failure. In this case, Mitotane Esteve treatment should be interrupted. Treatment can be resumed at physician's discretion depending on the severity of the event as well as the patient's clinical condition.

*Metabolism and nutrition disorders:* Regardless of Mitotane Esteve dosage, triglycerides should be monitored regularly especially in patients with or at risk of dyslipidemia (such as metabolic syndrome, alcohol abuse, high fat diet...). Triglyceride-lowering therapy and discontinuation of Mitotane Esteve may be considered in case of severe hypertriglyceridemia as it is a potential cause of acute pancreatitis.

*Mitotane tissue accumulation:* Fat tissue can act as a reservoir for mitotane, resulting in a prolonged half-life and potential accumulation of mitotane. Consequently, despite a constant dose, mitotane levels may increase. Therefore, monitoring of mitotane plasma levels (e.g. every two months) is also necessary after interruption of treatment, as prolonged release of mitotane can occur. Caution and close monitoring of mitotane plasma levels are highly recommended when treating overweight patients and patients with recent weight loss.

*Central nervous system disorders:* Long-term continuous administration of high doses of mitotane may lead to reversible brain damage and impairment of function. Behavioural and neurological assessments should be made at regular intervals, especially when mitotane plasma levels exceed 20 mg/L (see section **Error! Reference source not found.**).

*Blood and lymphatic system disorders:* All blood cells can be affected with mitotane treatment. Leucopenia (including neutropenia), anemia and thrombocytopenia have been reported frequently during mitotane treatment (see section **Error! Reference source not found.**). Red blood cell, white blood cell and platelet counts should be monitored during mitotane treatment.

*Bleeding time:* Prolonged bleeding time has been reported in patients treated with mitotane. In some patients, in vitro bleeding time may be normal but with pathologic adenosine diphosphate (ADP)-induced platelet aggregation. This should be taken into account when surgery is considered (see section 4.8).

*Warfarin and coumarin-like anticoagulants:* When administering mitotane to patients on coumarin-like anticoagulants, patients should be closely monitored for a change in anticoagulant dose requirements (see section **Error! Reference source not found.**).

*Substances metabolised through cytochrome P450 and particularly cytochrome 3A4:* Mitotane is a hepatic enzyme inducer and it should be used with caution in case of concomitant use of medicinal products influenced by hepatic metabolism (see section **Error! Reference source not found.**).

*Premenopausal women:* Non-malignant ovarian macrocysts, often bilateral and multiple, have been observed with higher incidence in this population. The ovarian macrocysts may be symptomatic (e.g., pelvic pain or discomfort, vaginal bleeding or menstrual disorders) or asymptomatic. Isolated cases of complicated cysts have been reported (adnexal torsion and haemorrhagic cyst rupture). Improvement after mitotane discontinuation has been observed. Women should be urged to seek medical advice if they experience gynaecological symptoms such as bleeding and/or pelvic pain. Periodic ovarian

ultrasound monitoring is recommended in premenopausal women treated with mitotane.

*Paediatric population:* In children and adolescents, neuro-psychological retardation can be observed during mitotane treatment. In such cases, thyroid function should be investigated in order to identify a possible thyroid impairment linked to mitotane treatment.

#### **4.5 Interaction with other medicinal products and other forms of interaction**

*Spironolactone:* Mitotane must not be given in combination with spironolactone, since this active substance may block the action of mitotane (see section **Error! Reference source not found.**).

*Warfarin and coumarin-like anticoagulants:* Mitotane has been reported to accelerate the metabolism of warfarin through hepatic microsomal enzyme induction, leading to an increase in dose requirements for warfarin. Therefore, patients should be closely monitored for a change in anticoagulant dose requirements when mitotane is administered to patients on coumarin-like anticoagulants.

*Substances metabolised through cytochrome P450:* Mitotane has been shown to have an inductive effect on cytochrome P450 enzymes. Therefore, the plasma concentrations of the substances metabolised via cytochrome P450 may be modified. In the absence of information on the specific P450 isoenzymes involved, caution should be taken when co-prescribing active substances metabolised by this route such as, among others, anticonvulsants, rifabutin, rifampicin, griseofulvin and St. John's wort (*Hypericum perforatum*). Particularly, mitotane has been shown to have an inductive effect on cytochrome 3A4. Therefore, the plasma concentrations of the substances metabolised via cytochrome 3A4 may be modified. Caution should be taken when co-prescribing active substances metabolised by this pathway such as, among others, sunitinib, etoposide and midazolam and dose should be adjusted as appropriate when coadministered with mitotane. Enzyme induction is likely to persist after discontinuation of mitotane treatment.

*Medicinal products active on central nervous system:* Mitotane can cause central nervous system undesirable effects at high concentrations (see section 17). Although no specific information on pharmacodynamic interactions in the central nervous system is available, this should be borne in mind when coprescribing medicinal products with central nervous system depressant action.

*Fat-rich food:* Data with various mitotane formulations suggest that administration with fat-rich food enhances absorption of mitotane.

*Hormone binding protein:* Mitotane has been shown to increase plasma levels of hormone binding proteins (e.g. sex hormone-binding globulin (SHBG) and corticosteroid-binding globulin (CBG)). This should be taken into account when interpreting the results of hormonal assays and may result in gynaecomastia.

## 4. CLINICAL PARTICULARS

### 4.6 Fertility, pregnancy and lactation

#### Pregnancy

Data, based on a limited number of exposed pregnancies indicate abnormalities on the adrenals of the foetus after exposure to mitotane. Mitotane has been detected in foetal cord blood. Pregnant women should be advised of a potential risk to the foetus. Animal reproduction studies have not been conducted with mitotane. Animal studies with similar substances have shown reproductive toxicity (see section **Error! Reference source not found.**). Mitotane Esteve is not recommended during pregnancy and in women of childbearing potential not using contraception.

#### Women of childbearing potential

Women of childbearing potential must use an effective contraception during treatment and after discontinuation of treatment as long as mitotane plasma levels are detectable, which may require several months. The prolonged elimination of mitotane from the body after discontinuation of Mitotane Esteve should be considered (see section 5.2).

#### Breast-feeding

Due to the lipophilic nature of mitotane, it is likely to be excreted in breast milk. Because of the potential for serious adverse reactions in the breastfed infant, breast-feeding is contraindicated while taking mitotane (see section **Error! Reference source not found.**) and after treatment discontinuation as long as mitotane plasma levels are detectable.

## 5. CLINICAL PARTICULARS

### 4.7 Effects on ability to drive and use machines

Mitotane Esteve has a major influence on the ability to drive and use machines. Ambulatory patients should be warned not to drive or use machines.

### 4.8 Undesirable effects

Safety data are based on literature (mainly retrospective studies). More than 80 % of patients treated with mitotane have shown at least one type of undesirable effect. Adverse reactions listed below are classified according to frequency and system organ class. Frequency groupings are defined according to the following convention: Very common ( $\geq 1/10$ ), Common ( $\geq 1/100$  to  $< 1/10$ ), Uncommon ( $\geq 1/1,000$  to  $< 1/100$ ), Rare ( $\geq 1/10,000$  to  $< 1/1,000$ ), Very rare ( $< 1/10,000$ ), Not known (cannot be estimated from the available data).

Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.

Table 1: Frequency of adverse reactions

System Organ Class	Adverse reaction		
	Very common	Common	Not Known
<i>Infections and infestations</i>			Opportunistic infection
<i>Blood and lymphatic</i>	Leukopenia	Anaemia	

<i>system disorders</i>	Bleeding time prolonged	Thrombocytopenia	
<i>Immune system disorders</i>			Hypersensitivity reactions
<i>Endocrine disorders</i>	Adrenal insufficiency		Thyroid disorder Hypogonadism (in males)
<i>Metabolism and nutrition disorders</i>	Decreased appetite Hypercholesterolemia Hypertriglyceridaemia		Hypouricaemia
<i>Psychiatric disorders</i>	Confusional state		
<i>Nervous system disorders</i>	Ataxia Paraesthesia Vertigo Somnolence	Mental impairment Polyneuropathy Movement disorder Dizziness Headache	Balance disorder
<i>Eye disorders</i>			Maculopathy Retinal toxicity Diplopia Lenticular opacities Visual impairment Vision blurred
<i>Vascular disorders</i>			Hypertension Orthostatic hypotension Flushing
<i>Gastrointestinal disorders</i>	Mucosal inflammation Vomiting Diarrhoea Nausea Epigastric discomfort		Salivary hypersecretion Dysgeusia Dyspepsia
<i>Hepatobiliary disorders</i>	Elevated liver enzymes	Autoimmune hepatitis	Liver injury (hepatocellular/cholestatic /mixed)
<i>Skin and subcutaneous tissue disorders</i>	Skin rash		Pruritus
<i>Musculoskeletal and connective tissue disorders</i>	Muscular weakness		
<i>Renal and urinary disorders</i>			Cystitis haemorrhagic Haematuria Proteinuria
<i>Reproductive system and breast disorders</i>	Gynaecomastia		Ovarian macrocysts
<i>General disorders and administration site conditions</i>	Asthenia		Hyperpyrexia Generalised aching
<i>Investigations</i>	Blood cholesterol increased Blood triglycerides increased		Blood uric acid decreased Blood androstenedione decreased (in females) Blood testosterone decreased (in females) Sex hormone binding globulin increased Blood testosterone free decreased (in males) Corticosteroid binding globulin increased

			Thyroxin binding globulin increased
--	--	--	-------------------------------------

*Description of selected adverse reactions*

Gastrointestinal disorders are the most frequently reported (10 to 100 % of patients) and are reversible when the dose is reduced. Some of these effects (anorexia) may constitute the hallmark of initial central nervous system impairment.

Nervous system undesirable effects occur in approximately 40 % of patients. Other undesirable central nervous effects have been reported in literature such as memory defects, aggressiveness, central vestibular syndrome, dysarthria, or Parkinson syndrome. Serious undesirable effects appear linked to the cumulative exposure to mitotane and are most likely to occur when mitotane plasma levels are at 20 mg/L or above. At high doses and after prolonged utilization, brain function impairment can occur. Nervous system undesirable effects appear reversible after cessation of mitotane treatment and decrease in plasma levels (see section **Error! Reference source not found.**).

Skin rashes which have been reported in 5 to 25 % of patients do not seem to be dose related.

Leucopenia has been reported in 8 to 12 % of patients. Prolonged bleeding time appears a frequent finding (90 %): although the exact mechanism of such an effect is unknown and its relation with mitotane or with the underlying disease is uncertain, it should be taken into account when surgery is considered.

The activity of liver enzymes (gamma-GT, aminotransferase, alkaline phosphatase) is commonly increased. Liver enzymes levels usually normalize when the mitotane dose is decreased or temporarily interrupted or discontinued. However, autoimmune hepatitis has been reported in 7 % of patients with no other information on mechanism. Very rare serious cases of liver injury (acute hepatic failure and hepatic encephalopathy) have been observed.

Hypogonadism: Hypogonadism in males (with symptoms such as gynaecomastia, libido decreased, erectile dysfunction, fertility disorders) has been described.

*Premenopausal women*

Non-malignant ovarian macrocysts (with symptoms such as pelvic pain, vaginal bleeding, menstrual disorders or asymptomatic) have been described.

*Paediatric population*

Neuro-psychological retardation may be observed during mitotane treatment. In such cases, thyroid function should be investigated in order to identify a possible thyroid impairment linked to mitotane treatment. Hypothyroidism and growth retardation may be also observed. One case of encephalopathy has been observed in a paediatric patient five months after initiation of the treatment; this case was considered to be related to an increased mitotane plasma level of 34.5 mg/L. After six months mitotane plasma levels were undetectable and the patient recovered clinically.

Oestrogenic-like effects (such as gynaecomastia in male patients and breast development and/or vaginal bleeding in female patients) have been observed.

### *Reporting of suspected adverse reactions*

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme

Website: [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard) or search for MHRA Yellow Card in the Google Play or Apple App Store.

## **6. CLINICAL PARTICULARS**

### **4.9 Overdose**

Mitotane overdose may lead to central nervous system impairment especially if mitotane plasma levels are above 20 mg/L. No proven antidotes have been established for mitotane overdose. Temporary interruption of Mitotane Esteve should be considered. The patient should be followed closely, taking into account that impairment is reversible, but given the long half-life and the lipophilic nature of mitotane, it may take weeks to return to normal. Other effects should be treated symptomatically. Because of its lipophilic nature, mitotane is not likely to be dialysable.

It is recommended to increase frequency of mitotane plasma level monitoring (e.g. every two weeks) in patients at risk of overdose (e.g. in case of renal or hepatic impairment, obese patients or patients with a recent weight loss).

## **5 PHARMACOLOGICAL PROPERTIES**

### **5.1 *Pharmacodynamic properties***

Pharmacotherapeutic group: Other antineoplastic agents, ATC code: L01XX23

#### Mechanism of action

Mitotane is an adrenal cytotoxic active substance, although it can apparently also cause adrenal inhibition without cellular destruction. Its biochemical mechanism of action is unknown. Available data suggest that mitotane modifies the peripheral metabolism of steroids and that it also directly suppresses the adrenal cortex. The administration of mitotane alters the extra-adrenal metabolism of cortisol in humans, leading to a reduction in measurable 17-hydroxy corticosteroids, even though plasma levels of corticosteroids do not fall. Mitotane apparently causes increased formation of 6-beta-hydroxy cholesterol.

#### Clinical efficacy

Mitotane has not been studied in a comprehensive clinical development program. Available clinical information comes mainly from published data in patients with inoperable or metastatic adrenal carcinoma. In terms of overall survival, four studies conclude that mitotane treatment does not increase the survival rate whereas five find an increase in the survival rate. Among the latter, three studies find such an increase only in patients in whom mitotane plasma is above 14 mg/l.

Mitotane plasma levels and the possible relationship with its efficacy were studied in the FIRM ACT trial, a randomized, prospective, controlled, open-label, multicenter, parallel-group study to compare the efficacy of etoposide, doxorubicin and cisplatin plus mitotane (EDP/M) to that of streptozotocin plus mitotane (Sz/M) as first-line

treatment in 304 patients. The analysis of patients who achieved mitotane levels  $\geq 14$  mg/l at least once in 6 six months versus patients who mitotane levels were  $< 14$  mg/l could suggest that patients with mitotane plasma levels  $\geq 14$  mg/l could have an improvement in disease control rate (62.9% versus 33.5%;  $p < 0.0001$ ). However, this result should be cautiously taken since the examination of the mitotane effects was not the primary endpoint of the study.

In addition, mitotane induces a state of adrenal insufficiency which leads to the disappearance of Cushing syndrome in patients with secreting adrenal carcinoma and necessitates substitution hormone therapy.

#### *Paediatric patients*

Clinical information comes mainly from a prospective trial (n= 24 patients) in children and adolescents aged at diagnosis from 5 months to 16 years (median age: 4 years) who had an unresectable primary tumour or who presented a tumour recurrence or a metastatic disease; most of the children (75%) presented with endocrine symptoms. Mitotane was given alone or combined with chemotherapy with various agents. Overall, the disease-free interval was 7 months (2 to 16 months). There were recurrences in 40% of children; the survival rate at 5 years was 49%.

## **7. PHARMACOLOGICAL PROPERTIES**

### **5.2 Pharmacokinetic properties**

#### Absorption

In a study performed in 8 patients with adrenal carcinoma treated with 2 to 3 g daily of mitotane, a highly significant correlation was found between plasma mitotane concentration and the total mitotane dose. The target plasma mitotane concentration (14 mg/L) was reached in all patients within 3 to 5 months and the total mitotane dose ranged between 283 and 387 g (median value: 363 g). The threshold of 20 mg/L was reached for cumulative amounts of mitotane of approximately 500 g. In another study, 3 patients with adrenal carcinoma received Mitotane Esteve according to a precise protocol allowing fast introduction of a high dose if the product was well tolerated: 3 g (as 3 intakes) on day 1, 4.5 g on day 2, 6 g on day 3, 7.5 g on day 4 and 9 g on day 5. This dose of Mitotane Esteve was continued or decreased in function of side effects and plasma mitotane levels. There was a positive linear correlation between the cumulative dose of Mitotane Esteve and the plasma levels of mitotane. In two of the 3 patients, plasma levels of more than 14 mg/L were achieved within 15 days and in one of them levels above 20 mg/L were achieved within approximately 30 days. In addition, in both studies, in some patients, the plasma mitotane levels continued to rise despite maintenance or a decrease of the daily dose of mitotane.

#### Distribution

Autopsy data from patients show that mitotane is found in most tissues of the body, with fat as the primary site of storage.

#### Biotransformation

Metabolism studies in man have identified the corresponding acid, 1,1-(o,p'-dichlorodiphenyl) acetic acid (o,p'-DDA), as the major circulating metabolite, together with smaller quantities of the 1,1-(o,p'-dichlorodiphenyl)-2,2 dichloroethene (o,p'-DDE) analogue of mitotane. No unchanged mitotane has been found in bile or in urine, where o,p'-DDA predominates, together with several of its hydroxylated metabolites. For induction with cytochrome P450, see section 4.5.

#### Elimination

After intravenous administration, 25% of the dose was excreted as metabolites within 24 hours.

Following discontinuation of mitotane treatment, it is slowly released from storage sites in fat, leading to reported terminal plasma half-lives ranging from 18 to 159 days.

### **5.3 *Preclinical safety data***

Non-clinical data on the general toxicity of mitotane is limited.

Reproductive toxicity studies have not been performed with mitotane. However, dichlorodiphenyltrichlorethane (DDT) and other polychlorinated biphenyl analogues are known to have deleterious effects on fertility, pregnancy and development, and mitotane could be expected to share these properties.

The genotoxic and carcinogenic potential of mitotane has not been investigated.

## **6 PHARMACEUTICAL PARTICULARS**

### **6.1 *List of excipients***

Maize starch  
Microcrystalline cellulose (E 460)  
Macrogol 3350  
Silica colloidal anhydrous

### **6.2 *Incompatibilities***

Not applicable.

### **6.3 *Shelf life***

3 years.

*After opening:* 1 year.

### **6.4 *Special precautions for storage***

Store in the original packaging.

### **6.5** *Nature and contents of container*

Square opaque white HDPE bottle having a thread on the mouth containing 100 tablets.  
Pack size of 1 bottle.

### **6.6** *Special precautions for disposal*

This medicinal product should not be handled by persons other than the patient and his/her caregivers, and especially not by pregnant women. Caregivers should wear disposable gloves when handling the tablets.

Any unused product or waste material should be disposed of in accordance with local requirements for cytotoxic medicinal products.

## **7** **MARKETING AUTHORISATION HOLDER**

Esteve Pharmaceuticals S.A.  
Passeig De La Zona Franca 109 Planta 4  
08038 Barcelona  
Spain

## **8** **MARKETING AUTHORISATION NUMBER(S)**

PL 08498/0040

## **9** **DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 01/01/2021  
Date of last renewal:

## **10** **DATE OF REVISION OF THE TEXT**

17/04/2026